AU2017344040A1 - Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases - Google Patents

Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases Download PDF

Info

Publication number
AU2017344040A1
AU2017344040A1 AU2017344040A AU2017344040A AU2017344040A1 AU 2017344040 A1 AU2017344040 A1 AU 2017344040A1 AU 2017344040 A AU2017344040 A AU 2017344040A AU 2017344040 A AU2017344040 A AU 2017344040A AU 2017344040 A1 AU2017344040 A1 AU 2017344040A1
Authority
AU
Australia
Prior art keywords
active ingredient
pharmaceutical composition
cannabinoid
cannabinoids
minor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017344040A
Other languages
English (en)
Inventor
Andrea Small-Howard
Helen TURNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GBS Global Biopharma Inc
Original Assignee
GBS Global Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GBS Global Biopharma Inc filed Critical GBS Global Biopharma Inc
Publication of AU2017344040A1 publication Critical patent/AU2017344040A1/en
Priority to AU2023222872A priority Critical patent/AU2023222872A1/en
Priority to AU2025213702A priority patent/AU2025213702A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2017344040A 2016-10-11 2017-10-10 Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases Abandoned AU2017344040A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2023222872A AU2023222872A1 (en) 2016-10-11 2023-08-30 Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
AU2025213702A AU2025213702A1 (en) 2016-10-11 2025-08-11 Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662406764P 2016-10-11 2016-10-11
US62/406,764 2016-10-11
PCT/US2017/055989 WO2018071452A1 (en) 2016-10-11 2017-10-10 Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023222872A Division AU2023222872A1 (en) 2016-10-11 2023-08-30 Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
AU2017344040A1 true AU2017344040A1 (en) 2019-04-18

Family

ID=60382587

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017344040A Abandoned AU2017344040A1 (en) 2016-10-11 2017-10-10 Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
AU2023222872A Abandoned AU2023222872A1 (en) 2016-10-11 2023-08-30 Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
AU2025213702A Pending AU2025213702A1 (en) 2016-10-11 2025-08-11 Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2023222872A Abandoned AU2023222872A1 (en) 2016-10-11 2023-08-30 Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
AU2025213702A Pending AU2025213702A1 (en) 2016-10-11 2025-08-11 Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases

Country Status (8)

Country Link
US (3) US10653640B2 (cg-RX-API-DMAC7.html)
EP (1) EP3525823B1 (cg-RX-API-DMAC7.html)
JP (2) JP7225103B2 (cg-RX-API-DMAC7.html)
CN (2) CN115887440A (cg-RX-API-DMAC7.html)
AU (3) AU2017344040A1 (cg-RX-API-DMAC7.html)
CA (1) CA3039413A1 (cg-RX-API-DMAC7.html)
IL (1) IL265902B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018071452A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
WO2018205022A1 (en) 2017-05-08 2018-11-15 Inmed Pharmaceuticals Inc. Ocular drug delivery formulation
WO2018217803A2 (en) 2017-05-22 2018-11-29 Growblox Life Sciences L.L.C. Myrcene-containing complex mixtures targeting trpv1
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
EP3796903A1 (en) 2018-05-22 2021-03-31 GBS Global Biopharma, Inc. Cannabinoids and/or terpenes for use in trpv1 modulation
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
EP3902538A4 (en) * 2018-12-29 2023-01-18 Buzzelet Development And Technologies Ltd ISOLATED OR SYNTHETIC CANNABINOID COMPOSITIONS WITH SELECTED TERPEN BLEND AND METHODS OF USE THEREOF
SG11202111809XA (en) * 2019-04-24 2021-11-29 Inmed Pharmaceuticals Inc Compositions and methods for use of cannabinoids for neuroprotection
CA3144983A1 (en) * 2019-06-28 2020-12-30 Gbs Global Biopharma, Inc. Treatment of pain using allosteric modulator of trpv1
US20220241239A1 (en) * 2019-07-17 2022-08-04 Zealand Pharma A/S Pharmaceutical composition for subcutaneous administration
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US20210100737A1 (en) 2019-10-03 2021-04-08 Starton Therapeutics, Inc. Transdermal delivery of dronabinol
CN113694049B (zh) * 2020-05-21 2022-11-22 汉义生物科技（北京）有限公司 大麻素类化合物及其在治疗帕金森症中的应用
MX2023000314A (es) * 2020-08-17 2023-02-22 Pike Therapeutics Inc Formulaciones farmaceuticas transdermicas de cannabinoides.
WO2022040367A2 (en) * 2020-08-18 2022-02-24 Gbs Global Biopharma, Inc. Cannabinoid-containing complex mixtures for the treatment of cytokine release syndrome while preserving key anti-viral immune reactions
EP4124336B1 (en) 2021-07-30 2023-10-25 Cannamedical Pharma GmbH Transmucosal patch comprising a cannabinoid and/or an opioid
CN113368086B (zh) * 2021-08-11 2021-12-03 龙麻(上海)医药研发有限责任公司 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用
US20230263766A1 (en) * 2021-09-28 2023-08-24 Gbs Global Biopharma, Inc. Cannabinoid-containing formulations for parkinsonian movement disorders
WO2024148117A2 (en) * 2023-01-04 2024-07-11 Florascience Inc. Methods of treating neurodegenerative diseases or conditions
WO2024160792A1 (en) 2023-01-30 2024-08-08 Cannamedical Pharma Gmbh Improved transmucosal patch comprising a cannabinoid and/or an opioid

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8207733A (pt) 1981-06-04 1983-05-10 Pharmasol Corp Recipiente pressurizado com bomba de suprimento
US4778810A (en) 1987-01-08 1988-10-18 Nastech Pharmaceutical Co., Inc. Nasal delivery of caffeine
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
JP2002510603A (ja) 1998-04-08 2002-04-09 イーライ・リリー・アンド・カンパニー ラロキシフェンの肺および鼻腔デリバリー
US6403126B1 (en) 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
DE10051427C1 (de) 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
CA2533400C (en) * 2001-02-14 2017-01-03 Gw Pharma Limited Cannabinoids pharmaceutical formulations
GB2391865B (en) * 2002-08-14 2005-06-01 Gw Pharma Ltd Improvements in the extraction of pharmaceutically active components from plant materials
US20060241130A1 (en) * 2003-01-31 2006-10-26 Ehud Keinan Anti-inflammatory compositions and uses thereof
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
US20110257256A1 (en) * 2008-07-31 2011-10-20 Bionoria Research Gmbh Cannabinoids for use in treating or preventing cognitive impairment and dementia
US8277781B2 (en) 2009-03-13 2012-10-02 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
MX2011011514A (es) 2009-04-28 2011-11-18 Alltranz Inc Formulaciones de canabidiol y metodos para utilizarlas.
US9066910B2 (en) 2010-04-15 2015-06-30 Steven Rosenblatt Methods and compositions of cannabis extracts
GB2491118B (en) * 2011-05-20 2015-12-30 Otsuka Pharma Co Ltd Cannabinoids for use in the treatment of neuropathic pain
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
WO2014145490A2 (en) * 2013-03-15 2014-09-18 Biotech Institute, Llc Breeding, production, processing and use of specialty cannabis
US20160108004A1 (en) * 2013-05-24 2016-04-21 Nestec S.A. Treatment or prevention of neurodegenerative disorders using menthol, linalool and/or icilin
US9763991B2 (en) * 2013-06-13 2017-09-19 Cannabis Science International Holding B.V. Composition for the treatment of neurobehavioral disorders
US20150057342A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
CN114191420A (zh) 2014-05-29 2022-03-18 雷迪厄斯制药公司 稳定的大麻素类化合物制剂
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
DK3258942T3 (da) 2015-02-16 2021-01-25 Apirx Pharmaceutical Usa Llc Kosmetiske og topiske sammensætninger omfattende cannabigerol og cannabidiol
US20160250270A1 (en) * 2015-02-27 2016-09-01 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
WO2017193072A1 (en) * 2016-05-06 2017-11-09 Harvest Direct Enterprises Llc The manufacturing methods, compositions, and medical applications of orally administered cannabis pharmaceuticals

Also Published As

Publication number Publication date
JP2019530751A (ja) 2019-10-24
WO2018071452A1 (en) 2018-04-19
JP2023058599A (ja) 2023-04-25
JP7225103B2 (ja) 2023-02-20
IL265902B1 (en) 2023-12-01
AU2025213702A1 (en) 2025-09-04
US20180098948A1 (en) 2018-04-12
US20200338017A1 (en) 2020-10-29
IL265902A (en) 2019-06-30
EP3525823B1 (en) 2024-04-24
AU2023222872A1 (en) 2023-09-21
US20250108016A1 (en) 2025-04-03
CN115887440A (zh) 2023-04-04
US10653640B2 (en) 2020-05-19
US11980592B2 (en) 2024-05-14
CN109963595B (zh) 2023-02-03
EP3525823A1 (en) 2019-08-21
CN109963595A (zh) 2019-07-02
IL265902B2 (en) 2024-04-01
CA3039413A1 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
US20250108016A1 (en) Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
US20240269089A1 (en) Myrcene-containing complex mixtures targeting trpv1
EP3576724B1 (en) Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
CN101939017B (zh) 大麻素在与抗精神病药物组合中的用途
US20230087359A1 (en) Cannabinoid compositions and methods of use thereof
US20200405657A1 (en) Treatment of pain using allosteric modulator of trpv1
HK40012464B (en) Cannabinoid-containing complex mixtures for the treatment of parkinson's disease
HK40012464A (en) Cannabinoid-containing complex mixtures for the treatment of parkinson's disease
CA3234083A1 (en) Cannabinoid-containing formulations for parkinsonian movement disorders
HK40019031B (en) Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
HK40019031A (en) Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted